5 Undervalued Oncology Stocks Wall Street Is Overlooking

Oncology spending is projected to reach $441 billion by 2029, but market growth is expected to slow as established therapies face generic and biosimilar competition. Several oncology blockbusters are also approaching loss of exclusivity, including Pfizer's Ibrance in 2027–2028 and Bristol Myers Squibb's Opdivo in 2028–2030. Overall, the oncology rally has been broad, but I believe several underappreciated companies still offer meaningful upside.

Seeking Alpha • Sep 18, 2026

Midterms Won't Settle Washington's Volatility

Political volatility should stay elevated even after Democrats retake the House this November, State Street Investment Management said. Republicans are still expected to hold the Senate, leaving little room for sweeping legislation.

ETF Trends • Sep 16, 2026

Heard on the Street: With the Food and Drug Administration's hard-liners gone, investors are rushing back into rare-disease bets

With the Food and Drug Administration's hard-liners gone, investors are rushing back into rare-disease bets.

WSJ • Sep 16, 2026

State Street XLV vs. iShares IXJ: Here's How These Healthcare ETFs Stack Up for Investors

XLV has a significantly lower expense ratio of 0.08% compared to IXJ's 0.38%. IXJ provides broader exposure with 110 holdings across global markets, while XLV concentrates on 60 domestic S&P 500 stocks.

The Motley Fool • Sep 13, 2026

Blend Innovative Growth & Defense With Healthcare ETFs

All too often, when investors look at the healthcare sector, they mostly see its value for its defensive merits. However, that view may be shortsighted and miss the broader picture in today's market.

ETF Trends • Sep 11, 2026

Midterm Takes Center Stage: What Does It Mean for Markets & ETFs?

Trump's midterm push, election uncertainty and AI's political scrutiny could shape markets. Explore ETFs positioned for potential sector and post-election gains.

Zacks Investment Research • Sep 11, 2026

XLE, XLF & XLV Forecast: Energy Eyes Breakout as XLV Slips

XLE eyes fresh highs as oil rises, while XLF consolidates and XLV tests key support after breaking below a major trendline.

FXEmpire • Sep 9, 2026

Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%

A failed cholesterol trial from Novartis (NYSE:NVS | NVS Price Prediction) is dragging the Lp(a) drug class lower and hitting Amgen (NASDAQ:AMGN) harder than any large-cap peer in Tuesday trading.

24/7 Wall Street • Sep 8, 2026

Health Care's Next Act: Tailwinds Emerging Across R&D Cycle

Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation. Companies like JNJ and AZN, with diversified portfolios and strong R&D pipelines, are better positioned to offset looming patent cliffs.

Seeking Alpha • Sep 8, 2026

If the Fed Hikes Interest Rates This Month, History Says This Is the Smartest ETF to Buy Right Now

The State Street Health Care Select Sector SPDR ETF could be a rising rates winner. It easily outpaced the broader market when the Fed hiked rates in 2022.

The Motley Fool • Sep 7, 2026